Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited first quarterly report for 2025, covering the period ending March 31, 2025. The report, prepared according to PRC Accounting Standards, was approved by the board of directors, with all directors in attendance. The company emphasizes the accuracy and completeness of the report, reflecting its commitment to transparency and accountability in its financial disclosures.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development and production of pharmaceutical products.
YTD Price Performance: 11.11%
Average Trading Volume: 3,890,561
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.5B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.